生存预后-话题@MedSci - 梅斯（MedSci）

#生存预后#

30篇内容 | 1647人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=2041315, encodeId=8e0a2041315c3, content=<a href='/topic/show?id=2f826902418' target=_blank style='color:#2F92EE;'>#生存预后#</a>, objectTitle=J Clin Oncol：埃罗妥珠单抗联合泊马度胺和地塞米松可显著改善复发/难治性多发性骨髓瘤生存预后, objectType=article, longId=736048, objectId=4468e3604828, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4468e3604828, replyNumber=0, likeNumber=118, createdTime=2023-05-06, rootId=0, userName=heli0118, userId=21015, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4468e3604828, moduleTitle=J Clin Oncol：埃罗妥珠单抗联合泊马度胺和地塞米松可显著改善复发/难治性多发性骨髓瘤生存预后, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=4468e3604828)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2041316, encodeId=e7f22041316d8, content=<a href='/topic/show?id=2f826902418' target=_blank style='color:#2F92EE;'>#生存预后#</a>, objectTitle=J Clin Oncol：奥拉帕尼维持治疗晚期卵巢癌随访长达7年的总生存预后, objectType=article, longId=739397, objectId=5287e39397ac, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5287e39397ac, replyNumber=0, likeNumber=98, createdTime=2023-08-30, rootId=0, userName=heli0118, userId=21015, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5287e39397ac, moduleTitle=J Clin Oncol：奥拉帕尼维持治疗晚期卵巢癌随访长达7年的总生存预后, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=5287e39397ac)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2041314, encodeId=f57f2041314f4, content=<a href='/topic/show?id=2f826902418' target=_blank style='color:#2F92EE;'>#生存预后#</a>, objectTitle=2022 ASCO：派姆单抗联合化疗可显著提高早期三阴性乳腺癌的生存预后, objectType=article, longId=728384, objectId=e24ae28384d8, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e24ae28384d8, replyNumber=0, likeNumber=115, createdTime=2022-07-18, rootId=0, userName=heli0118, userId=21015, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e24ae28384d8, moduleTitle=2022 ASCO：派姆单抗联合化疗可显著提高早期三阴性乳腺癌的生存预后, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=e24ae28384d8)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2041307, encodeId=26dc204130ed0, content=<a href='/topic/show?id=2f826902418' target=_blank style='color:#2F92EE;'>#生存预后#</a>, objectTitle=Lancet oncol：替莫唑胺辅助治疗可改善放疗后的间变性胶质细胞瘤患者的生存预后！, objectType=article, longId=293001, objectId=3e2e29300136, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3e2e29300136, replyNumber=0, likeNumber=84, createdTime=2022-03-30, rootId=0, userName=heli0118, userId=21015, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3e2e29300136, moduleTitle=Lancet oncol：替莫唑胺辅助治疗可改善放疗后的间变性胶质细胞瘤患者的生存预后！, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=3e2e29300136)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2041313, encodeId=ef99204131301, content=<a href='/topic/show?id=2f826902418' target=_blank style='color:#2F92EE;'>#生存预后#</a>, objectTitle=JAMA Oncol：紫杉醇+顺铂+卡培他滨诱导化疗可改善晚期鼻咽癌患者的生存预后, objectType=article, longId=302272, objectId=31553022e20d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=31553022e20d, replyNumber=0, likeNumber=123, createdTime=2022-08-30, rootId=0, userName=heli0118, userId=21015, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=31553022e20d, moduleTitle=JAMA Oncol：紫杉醇+顺铂+卡培他滨诱导化疗可改善晚期鼻咽癌患者的生存预后, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=31553022e20d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2041312, encodeId=da232041312a8, content=<a href='/topic/show?id=2f826902418' target=_blank style='color:#2F92EE;'>#生存预后#</a>, objectTitle=Eur J Cancer：术后辅助立体定向放疗可改善边缘切除的肝癌患者的生存预后, objectType=article, longId=301375, objectId=297c3013e538, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=297c3013e538, replyNumber=0, likeNumber=87, createdTime=2022-11-09, rootId=0, userName=heli0118, userId=21015, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=297c3013e538, moduleTitle=Eur J Cancer：术后辅助立体定向放疗可改善边缘切除的肝癌患者的生存预后, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=297c3013e538)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2041303, encodeId=127f204130376, content=<a href='/topic/show?id=2f826902418' target=_blank style='color:#2F92EE;'>#生存预后#</a>, objectTitle=Gynecol Oncol：鳞状细胞癌抗原（SCC-Ag）是局部晚期宫颈癌患者的生存预后因素, objectType=article, longId=217443, objectId=bacd21e4438e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=bacd21e4438e, replyNumber=0, likeNumber=105, createdTime=2022-06-28, rootId=0, userName=heli0118, userId=21015, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=bacd21e4438e, moduleTitle=Gynecol Oncol：鳞状细胞癌抗原（SCC-Ag）是局部晚期宫颈癌患者的生存预后因素, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=bacd21e4438e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2041305, encodeId=7aaf2041305e7, content=<a href='/topic/show?id=2f826902418' target=_blank style='color:#2F92EE;'>#生存预后#</a>, objectTitle=Lancet Oncol：SOLO1试验| 奥拉帕利维持治疗晚期卵巢癌随访5年的生存预后, objectType=article, longId=219747, objectId=c80a219e4706, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c80a219e4706, replyNumber=0, likeNumber=134, createdTime=2022-02-28, rootId=0, userName=heli0118, userId=21015, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c80a219e4706, moduleTitle=Lancet Oncol：SOLO1试验| 奥拉帕利维持治疗晚期卵巢癌随访5年的生存预后, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=c80a219e4706)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2041311, encodeId=078b2041311fc, content=<a href='/topic/show?id=2f826902418' target=_blank style='color:#2F92EE;'>#生存预后#</a>, objectTitle=Eur J Cancer：卡培他滨辅助治疗对乳腺癌患者生存预后的影响, objectType=article, longId=301290, objectId=7dff30129033, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7dff30129033, replyNumber=0, likeNumber=112, createdTime=2022-06-14, rootId=0, userName=heli0118, userId=21015, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7dff30129033, moduleTitle=Eur J Cancer：卡培他滨辅助治疗对乳腺癌患者生存预后的影响, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=7dff30129033)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2041299, encodeId=aced20412993e, content=<a href='/topic/show?id=2f826902418' target=_blank style='color:#2F92EE;'>#生存预后#</a>, objectTitle=Cardiovasc Diabetol：降糖治疗对糖尿病透析患者生存预后的影响, objectType=article, longId=216876, objectId=90d12168e62b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=90d12168e62b, replyNumber=0, likeNumber=109, createdTime=2021-09-20, rootId=0, userName=heli0118, userId=21015, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=90d12168e62b, moduleTitle=Cardiovasc Diabetol：降糖治疗对糖尿病透析患者生存预后的影响, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=90d12168e62b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2041310, encodeId=107d2041310b1, content=<a href='/topic/show?id=2f826902418' target=_blank style='color:#2F92EE;'>#生存预后#</a>, objectTitle=JAMA Oncol：卡培他滨维持治疗可明显改善转移性鼻咽癌患者的生存预后, objectType=article, longId=299226, objectId=14fc299226be, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=14fc299226be, replyNumber=0, likeNumber=123, createdTime=2022-07-24, rootId=0, userName=heli0118, userId=21015, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=14fc299226be, moduleTitle=JAMA Oncol：卡培他滨维持治疗可明显改善转移性鼻咽癌患者的生存预后, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=14fc299226be)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2041298, encodeId=49682041298df, content=<a href='/topic/show?id=2f826902418' target=_blank style='color:#2F92EE;'>#生存预后#</a>, objectTitle=Blood：预测接受强化化疗的AML老年患者长期生存预后的新模型！, objectType=article, longId=216313, objectId=d2db2163135b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d2db2163135b, replyNumber=0, likeNumber=87, createdTime=2021-12-06, rootId=0, userName=heli0118, userId=21015, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d2db2163135b, moduleTitle=Blood：预测接受强化化疗的AML老年患者长期生存预后的新模型！, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=d2db2163135b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2041301, encodeId=c197204130127, content=<a href='/topic/show?id=2f826902418' target=_blank style='color:#2F92EE;'>#生存预后#</a>, objectTitle=J Clin Oncol：长春新碱-伊立替康方案加用替莫唑胺可改善复发/难治性横纹肌肉瘤患者的生存预后, objectType=article, longId=217221, objectId=d47b21e2212b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d47b21e2212b, replyNumber=0, likeNumber=121, createdTime=2021-11-21, rootId=0, userName=heli0118, userId=21015, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d47b21e2212b, moduleTitle=J Clin Oncol：长春新碱-伊立替康方案加用替莫唑胺可改善复发/难治性横纹肌肉瘤患者的生存预后, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=d47b21e2212b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2041308, encodeId=14722041308fb, content=<a href='/topic/show?id=2f826902418' target=_blank style='color:#2F92EE;'>#生存预后#</a>, objectTitle=Lancet oncol：单用avelumab或联合PLD可显著延长铂类耐药/难治性卵巢癌的生存预后, objectType=article, longId=293025, objectId=724d293025d7, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=724d293025d7, replyNumber=0, likeNumber=75, createdTime=2022-01-16, rootId=0, userName=heli0118, userId=21015, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=724d293025d7, moduleTitle=Lancet oncol：单用avelumab或联合PLD可显著延长铂类耐药/难治性卵巢癌的生存预后, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=724d293025d7)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2041309, encodeId=de472041309f4, content=<a href='/topic/show?id=2f826902418' target=_blank style='color:#2F92EE;'>#生存预后#</a>, objectTitle=Lancet Oncol：SOLO1试验| 奥拉帕利维持治疗晚期卵巢癌随访5年的生存预后, objectType=article, longId=293043, objectId=5aea293043a4, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5aea293043a4, replyNumber=0, likeNumber=73, createdTime=2022-08-24, rootId=0, userName=heli0118, userId=21015, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5aea293043a4, moduleTitle=Lancet Oncol：SOLO1试验| 奥拉帕利维持治疗晚期卵巢癌随访5年的生存预后, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=5aea293043a4)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2041296, encodeId=034820412962d, content=<a href='/topic/show?id=2f826902418' target=_blank style='color:#2F92EE;'>#生存预后#</a>, objectTitle=Lancet oncol：单用avelumab或联合PLD可显著延长铂类耐药/难治性卵巢癌的生存预后, objectType=article, longId=212816, objectId=bee72128164e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=bee72128164e, replyNumber=0, likeNumber=82, createdTime=2022-03-06, rootId=0, userName=heli0118, userId=21015, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=bee72128164e, moduleTitle=Lancet oncol：单用avelumab或联合PLD可显著延长铂类耐药/难治性卵巢癌的生存预后, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=bee72128164e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2041300, encodeId=56ff20413007d, content=<a href='/topic/show?id=2f826902418' target=_blank style='color:#2F92EE;'>#生存预后#</a>, objectTitle=Lancet Oncol：只放疗不手术，IA期NSCLC患者的生存预后完全不输肺叶切除+淋巴结清扫！, objectType=article, longId=217218, objectId=98cb21e218a9, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=98cb21e218a9, replyNumber=0, likeNumber=95, createdTime=2022-08-23, rootId=0, userName=heli0118, userId=21015, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=98cb21e218a9, moduleTitle=Lancet Oncol：只放疗不手术，IA期NSCLC患者的生存预后完全不输肺叶切除+淋巴结清扫！, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=98cb21e218a9)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2041306, encodeId=6fcd2041306e1, content=<a href='/topic/show?id=2f826902418' target=_blank style='color:#2F92EE;'>#生存预后#</a>, objectTitle=BMC Cancer：徐兵河院士团队分析中国汉族人群转移性乳腺癌伴有同时性肺转移患者的临床病理特征和生存预后, objectType=article, longId=292795, objectId=4e9b292e95cc, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4e9b292e95cc, replyNumber=0, likeNumber=147, createdTime=2022-05-27, rootId=0, userName=heli0118, userId=21015, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4e9b292e95cc, moduleTitle=BMC Cancer：徐兵河院士团队分析中国汉族人群转移性乳腺癌伴有同时性肺转移患者的临床病理特征和生存预后, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=4e9b292e95cc)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2041304, encodeId=13dd2041304fc, content=<a href='/topic/show?id=2f826902418' target=_blank style='color:#2F92EE;'>#生存预后#</a>, objectTitle=Lancet Oncol：阿帕鲁胺联合阿比特龙-泼尼松可明显改善mCRPC患者的生存预后, objectType=article, longId=218148, objectId=fdff218148d4, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=fdff218148d4, replyNumber=0, likeNumber=103, createdTime=2022-06-30, rootId=0, userName=heli0118, userId=21015, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=fdff218148d4, moduleTitle=Lancet Oncol：阿帕鲁胺联合阿比特龙-泼尼松可明显改善mCRPC患者的生存预后, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=fdff218148d4)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2041295, encodeId=ba612041295b1, content=<a href='/topic/show?id=2f826902418' target=_blank style='color:#2F92EE;'>#生存预后#</a>, objectTitle=J Urol：膀胱切除术前新辅助化疗对肌肉浸润性膀胱癌的病理分期和生存预后的益处, objectType=article, longId=212006, objectId=50c321200648, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=50c321200648, replyNumber=0, likeNumber=90, createdTime=2022-03-08, rootId=0, userName=heli0118, userId=21015, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=50c321200648, moduleTitle=J Urol：膀胱切除术前新辅助化疗对肌肉浸润性膀胱癌的病理分期和生存预后的益处, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=50c321200648)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

生存预后

2020-05-29

heli0118 (审核中...)

前往app查看评论内容

#生存预后#

J Clin Oncol：埃罗妥珠单抗联合泊马度胺和地塞米松可显著改善复发/难治性多发性骨髓瘤生存预后

2023-05-06

heli0118 (审核中...)

前往app查看评论内容

#生存预后#

J Clin Oncol：奥拉帕尼维持治疗晚期卵巢癌随访长达7年的总生存预后

2023-08-30

heli0118 (审核中...)

前往app查看评论内容

#生存预后#

2022 ASCO：派姆单抗联合化疗可显著提高早期三阴性乳腺癌的生存预后

2022-07-18

heli0118 (审核中...)

前往app查看评论内容

#生存预后#

Lancet oncol：替莫唑胺辅助治疗可改善放疗后的间变性胶质细胞瘤患者的生存预后！

2022-03-30

heli0118 (审核中...)

前往app查看评论内容

#生存预后#

JAMA Oncol：紫杉醇+顺铂+卡培他滨诱导化疗可改善晚期鼻咽癌患者的生存预后

2022-08-30

heli0118 (审核中...)

前往app查看评论内容

#生存预后#

Eur J Cancer：术后辅助立体定向放疗可改善边缘切除的肝癌患者的生存预后

2022-11-09

heli0118 (审核中...)

前往app查看评论内容

#生存预后#

Gynecol Oncol：鳞状细胞癌抗原（SCC-Ag）是局部晚期宫颈癌患者的生存预后因素

2022-06-28

heli0118 (审核中...)

前往app查看评论内容

#生存预后#

Lancet Oncol：SOLO1试验| 奥拉帕利维持治疗晚期卵巢癌随访5年的生存预后

2022-02-28

heli0118 (审核中...)

前往app查看评论内容

#生存预后#

Eur J Cancer：卡培他滨辅助治疗对乳腺癌患者生存预后的影响

2022-06-14

heli0118 (审核中...)

前往app查看评论内容

#生存预后#

Cardiovasc Diabetol：降糖治疗对糖尿病透析患者生存预后的影响

2021-09-20

heli0118 (审核中...)

前往app查看评论内容

#生存预后#

JAMA Oncol：卡培他滨维持治疗可明显改善转移性鼻咽癌患者的生存预后

2022-07-24

heli0118 (审核中...)

前往app查看评论内容

#生存预后#

Blood：预测接受强化化疗的AML老年患者长期生存预后的新模型！

2021-12-06

heli0118 (审核中...)

前往app查看评论内容

#生存预后#

J Clin Oncol：长春新碱-伊立替康方案加用替莫唑胺可改善复发/难治性横纹肌肉瘤患者的生存预后

2021-11-21

heli0118 (审核中...)

前往app查看评论内容

#生存预后#

Lancet oncol：单用avelumab或联合PLD可显著延长铂类耐药/难治性卵巢癌的生存预后

2022-01-16

heli0118 (审核中...)

前往app查看评论内容

#生存预后#

Lancet Oncol：SOLO1试验| 奥拉帕利维持治疗晚期卵巢癌随访5年的生存预后

2022-08-24

heli0118 (审核中...)

前往app查看评论内容

#生存预后#

Lancet oncol：单用avelumab或联合PLD可显著延长铂类耐药/难治性卵巢癌的生存预后

2022-03-06

heli0118 (审核中...)

前往app查看评论内容

#生存预后#

Lancet Oncol：只放疗不手术，IA期NSCLC患者的生存预后完全不输肺叶切除+淋巴结清扫！

2022-08-23

heli0118 (审核中...)

前往app查看评论内容

#生存预后#

BMC Cancer：徐兵河院士团队分析中国汉族人群转移性乳腺癌伴有同时性肺转移患者的临床病理特征和生存预后

2022-05-27

heli0118 (审核中...)

前往app查看评论内容

#生存预后#

Lancet Oncol：阿帕鲁胺联合阿比特龙-泼尼松可明显改善mCRPC患者的生存预后

2022-06-30

heli0118 (审核中...)

前往app查看评论内容

#生存预后#

J Urol：膀胱切除术前新辅助化疗对肌肉浸润性膀胱癌的病理分期和生存预后的益处

2022-03-08

科室
- - 订阅+
  - 更多科室
工具
服务